Abstracts

DRUG CONCENTRATIONS AND BODY WEIGHT GAIN IN PLWH SWITCHED TO 3TC & DOLUTEGRAVIR (DTG)

Weight gain after initiation of DTG-containing ART has recently been reported in clinical trials and cohorts, but pathophysiology remains unclear.  In most switch studies, DTG was associated with a 2-NRTIs backbone.  We evaluated changes in body weight in virologically suppressed PLWH switched to 3TC plus DTG dual therapy (ANRS 167 Lamidol trial). Virologically suppressed patients…

TELMISARTAN DECREASES MONOCYTE CX3CR1 EXPRESSION IN TREATED HIV INFECTION

Telmisartan is an angiotensin receptor blocker and PPAR-g agonist that is active in adipose tissue (AT) and has anti-inflammatory properties. Secretion of fractalkine by adipocytes and expression of its receptor, CX3CR1, on monocytes/macrophages have been implicated in AT inflammation, obesity and cardiovascular disease (CVD). Fractalkine/CX3CR1 expression are mediated by PPAR-g suppression and endotoxemia, both sequelae of HIV.…